Encouraging data from stem cell trial in stroke patients as plans for Phase II progress

Medical Xpress: May 27, 2013

Updated interim data from the PISCES trial, which has seen the brains of ischaemic stroke patients injected with neural stem cells to test the safety and tolerability of the treatment, was presented to the 22nd European Stroke Conference in London today. Professor Keith Muir of the University of Glasgow, who is heading the trial of ReNeuron Group plc’s ReN001 stem cell therapy at the Southern General Hospital, Glasgow reported that data from the first nine patients treated has shown no cell-related or immunological adverse affects. He added that most patients had experienced sustained modest reductions in neurological impairment compared to their pre-treatment baseline performance, accompanied by improvement in abilities to undertake day to day tasks. A further two patients have been treated since the data were collated and the trial is now drawing to a close, with full results due to be published next year.    Read more